Roche Holding Ltd. (VTX:ROG) PT Set at CHF 260 by UBS AG
Roche Holding Ltd. (VTX:ROG) has been assigned a CHF 260 target price by equities researchers at UBS AG in a research note issued on Thursday, www.boersen-zeitung.de reports. The firm currently has a “neutral” rating on the healthcare company’s stock.
Several other equities analysts have also commented on the company. Sanford C. Bernstein set a CHF 284 price target on Roche Holding and gave the company a “buy” rating in a research note on Thursday. Morgan Stanley set a CHF 260 price target on Roche Holding and gave the company a “neutral” rating in a research note on Wednesday. Goldman Sachs Group, Inc. (The) set a CHF 335 price target on Roche Holding and gave the company a “buy” rating in a research note on Thursday, July 20th. J P Morgan Chase & Co restated a “buy” rating on shares of Roche Holding in a research note on Monday, July 17th. Finally, Jefferies Group LLC set a CHF 275 price target on Roche Holding and gave the company a “buy” rating in a research note on Wednesday, July 12th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and seven have given a buy rating to the company’s stock. Roche Holding currently has an average rating of “Hold” and a consensus target price of CHF 271.08.
Roche Holding (VTX ROG) opened at 245.50 on Thursday. The stock has a 50 day moving average of CHK 247.00 and a 200-day moving average of CHK 251.21. The company has a market capitalization of CHK 209.16 billion and a price-to-earnings ratio of 21.24. Roche Holding has a 52-week low of CHK 218.30 and a 52-week high of CHK 273.00.
COPYRIGHT VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/07/27/roche-holding-ltd-vtxrog-pt-set-at-chf-260-by-ubs-ag.html.
Roche Holding Company Profile
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.